International CML Foundation

23/04/2026

Latin American CML Physicians – Join the Discussion!

📅 Second Regional Discussion Group for 2026: May 21st
Topics:
✅ ELN 2025 recommendations - what’s most important for LA?
✅ Overcoming challenges to treatment adherence

⏰ Start times:
Mexico City – 17:00
Bogotá – 18:00
Buenos Aires / Rio de Janeiro / Santiago – 20:00

🌎 Online | Open to physicians treating CML across Latin America
🗣 Spanish interpretation available

Register now: https://buff.ly/SEFIO1h

22/04/2026

🩺 Honouring a lifetime dedicated to improving outcomes for children with CML

The 2026 iCMLf John Goldman Prize is awarded to Professor Meinolf Suttorp for his outstanding contributions to the understanding and treatment of pediatric CML.

For decades, Professor Suttorp has worked tirelessly to improve the outcomes for children and adolescents with CML. Through international clinical trials, global collaboration, and a strong commitment to pediatric-focused research, he has helped shape modern treatment strategies and advance outcomes for young patients with CML worldwide.

His work has addressed key challenges unique to pediatric CML - from long-term treatment effects to growth and development, and the potential for treatment-free remission - bringing both scientific insights and real-world impact to clinical practice.

👏 Congratulations, Professor Suttorp, and thank you for your lasting contribution to pediatric CML.

Read more about his achievements in the full recognition article: https://buff.ly/E4rKRVP

16/04/2026

Happening today!

The first Regional Discussion Group of 2026. And there's still time to join us

We'll be discussing First line therapy - is imatinib still the best frontline treatment?
Debate format.

Open to all physicians treating CML in Latin America.

Register here: https://buff.ly/SEFIO1h

15/04/2026

🔬 Recognising a lifetime of discovery in CML biology

The 2026 iCMLf Rowley Prize is awarded to Professor Junia Vaz de Melo for her pioneering contributions to uncovering the molecular mechanisms of chronic myeloid leukemia.

Professor Melo’s work has been instrumental in advancing our understanding of CML, from the role of BCR::ABL signalling and disease progression to the biology of leukemic stem cells. Her research also provided some of the earliest insights into treatment resistance, helping to inform the development of next-generation targeted therapies.

By bridging fundamental science with clinical application, her work has contributed to more precise and effective treatment strategies for patients with CML worldwide.

👏 Congratulations, Professor Melo, and thank you for your enduring impact on the global CML community.

Read more about her achievements: https://buff.ly/wHgD0dt

13/04/2026

Treating children, adolescents and young adults with CML comes with unique challenges - from diagnosis through long-term management and life beyond therapy.

Designed to support clinicians treating pediatric CML, our dedicated hub brings together global expertise and practical tools to support better management and outcomes, including:

1️⃣ iCMLf Knowledge Centre: Comprehensive review of pediatric CML treatment
2️⃣ Pediatric CML case reviews: an ongoing expert case series
3️⃣ Latest publications on pediatric CML
4️⃣ Clinical guidelines and recommendations for pediatric CML
5️⃣ Pediatric case discussions via our Clinical Case Discussion Forum
6️⃣ Ongoing clinical trials and research updates

Access all resources on pediatric CML here: https://buff.ly/IH4ROwA

10/04/2026

We are delighted to announce the 2026 iCMLf Prize winners, recognising outstanding contributions across the global CML community:

🏆 Rowley Prize – Professor Junia Vaz de Melo (Australia)
Honoured for pioneering research advancing the molecular understanding of CML, including mechanisms of disease progression and treatment resistance.

🏆 Goldman Prize – Professor Meinolf Suttorp (Germany)
Recognised for decades of leadership in pediatric CML, shaping clinical care, international trials, and treatment strategies for children and adolescents.

🏆 iCMLf Prize – Associate Professor Amha Gebremedhin (Ethiopia)
Awarded for transforming CML care in Ethiopia through improved access to diagnostics, treatment, and specialist training.

From discovery to clinical care to global access, their work reflects the full spectrum of progress in CML worldwide.

Learn more: https://buff.ly/Qoz9C5D

09/04/2026

There's still time to register for the first Regional Discussion Group of 2026!

Join our regional and international experts next Thursday as we discuss:
First line therapy - is imatinib still the best frontline treatment?
Debate format.

Register here: https://buff.ly/LurQgi5

Hope to see you there!

08/04/2026

Here are our selection of CML Papers for March curated by Prof. Tim Hughes.

Highlights include:

1️⃣ Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial
Cortes JE et al. Blood, March 2026
Open access publication
https://bit.ly/4bYCBKH

2️⃣ ELN 2025 and somatic NGS in CML: a pragmatic framework for selective testing and interpretation beyond BCR::ABL1
Mishra S et al. Leuk Lymphoma, March 2026 (epub ahead of print)
https://bit.ly/4tFnhJ0

3️⃣ BCR::ABL1 tyrosine kinase inhibitors induce ribosome collisions to activate ZAK-dependent ribotoxic stress and apoptosis in chronic myeloid leukemia
Park J et al. Leukemia, March 2026
Open access publication
https://bit.ly/3QqkEMu

4️⃣ Treatment-free remission in chronic myeloid leukemia in low- and middle-income countries
Annamalay A et al. N Engl J Med, March 2026
Open access publication
https://bit.ly/4sfuyhf

📖 Explore the full list of papers on our website:
https://bit.ly/4cwV0hN

03/04/2026

“The climbs are designed to be hard. That is intentional. A patient’s journey with CML… is not easy.”

As we conclude our week of Climb for a Cure updates, our CEO, Nicola Evans, reflects on this year’s journey in Ecuador - the challenge, the community, and what the climb truly represents for people living with CML worldwide.

Read Nicola’s reflections: https://buff.ly/gpEcQWs

Terns, Novartis , Enliven, Ascentage, SAHMRI

01/04/2026

From the foothills of Cotopaxi to over 4,600 metres, we climbed together for one shared purpose: improving outcomes for people living with CML worldwide.

The iCMLf Climb for a Cure 2026 brought patients, physicians, researchers, and supporters together in Ecuador - each step a reminder of what we can achieve as a global community.

Watch The Climb in Action to see what this journey meant to us - and what it represents for the future of CML care.

With thanks to our sponsors Novartis, Terns, Enliven, Ascentage, SAHMRI

🎥 Watch now

31/03/2026

This week, we’re sharing highlights from the iCMLf Climb for a Cure 2026 - and the collaboration and learning that took place around it.

The iCMLf Forum CML Without Borders: A Dialogue from the Andes brought international and Ecuadorian CML specialists together in Quito for a day of scientific exchange, clinical discussion, and shared learning.

Hosted at the Hospital de Especialidades Eugenio Espejo in collaboration with the Sociedad Ecuatoriana de Hematología, the forum connected leading global experts with clinicians and laboratory teams working directly with patients in Ecuador. From molecular diagnostics and mutation testing to first-line therapy and emerging treatments, the discussions focused on practical ways to strengthen CML care across Ecuador and Latin America.

More than a meeting, the forum helped lay the foundations for ongoing collaboration, training, and research across the Andean region.

Read the full story and discover how collaboration is advancing CML care worldwide: https://buff.ly/lN9kdmh

With thanks to Novartis for their support of the meeting

30/03/2026

🎧 New Blood Podcast featuring iCMLf Chairman, Dr. Jorge Cortes

In this week’s podcast from the American Society of Hematology, Dr. Jorge Cortes discusses new findings from the ASC4FIRST trial, recently published in Blood.

The analysis shows that asciminib demonstrated superior efficacy and a consistently favorable safety profile compared with investigator-selected TKIs in newly diagnosed chronic myeloid leukemia (CML), with particularly strong outcomes compared to second-generation TKIs. These findings further support asciminib as a promising frontline treatment option for patients with CML.

Listen to the full episode:

Blood Podcast | Blood | American Society of Hematology Blood Podcasts  Stay up to date on the latest research and reviews for both clinical and basic hematology with Blood podcasts, published weekly in conjunction with each issue of Blood. Additionally, Blood review series podcasts feature in d...